{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:31:49Z","timestamp":1792485109681,"version":"4.5.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:00:00Z","timestamp":1525392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,12]]},"DOI":"10.1093\/ibd\/izy153","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T15:30:12Z","timestamp":1539358212000},"page":"2431-2441","source":"Crossref","is-referenced-by-count":94,"title":["Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting"],"prefix":"10.1093","volume":"24","author":[{"given":"Siew C","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science, The Chinese University of Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Normiha","family":"Hilmi","sequence":"additional","affiliation":[{"name":"University Malaya Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Blake","sequence":"additional","affiliation":[{"name":"Takeda International - UK Branch, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Bhayat","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Adsul","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasim Rana","family":"Khan","sequence":"additional","affiliation":[{"name":"Emerging Markets Medical Affairs, Takeda Pharmaceuticals International AG Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Chyang","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,4]]},"reference":[{"key":"key\n\t\t\t\t20181012112705085_CIT0001","volume-title":"World Gastroenterology Organisation Global Guidelines. Inflammatory Bowel Disease","author":"Bernstein","year":"2015"},{"key":"key\n\t\t\t\t20181012112705085_CIT0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0003","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20181012112705085_CIT0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"key":"key\n\t\t\t\t20181012112705085_CIT0005","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20181012112705085_CIT0006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0007","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1185\/03007995.2015.1065242","article-title":"Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database","volume":"31","author":"McAuliffe","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20181012112705085_CIT0008","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","article-title":"Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening","volume":"7","author":"Jauregui-Amezaga","year":"2013","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0009","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3346\/jkms.2015.30.2.173","article-title":"The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-\u03b1 blockers","volume":"30","author":"Byun","year":"2015","journal-title":"J Korean Med Sci"},{"key":"key\n\t\t\t\t20181012112705085_CIT0010","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2016"},{"key":"key\n\t\t\t\t20181012112705085_CIT0011","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1756-185X.12467","article-title":"The long-term effects of anti-TNF-\u03b1 agents on patients with chronic viral hepatitis C and B infections","volume":"18","author":"Temel","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0012","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2893.2012.01643.x","article-title":"Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection","volume":"20","author":"Morisco","year":"2013","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20181012112705085_CIT0013","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"key\n\t\t\t\t20181012112705085_CIT0014","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20181012112705085_CIT0015","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14\u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0016","volume-title":"ENTYVIO\u00ae (vedolizumab) summary of product characteristics","author":"Takeda Pharma A\/S","year":"2014"},{"key":"key\n\t\t\t\t20181012112705085_CIT0017","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"key\n\t\t\t\t20181012112705085_CIT0018","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181012112705085_CIT0019","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181012112705085_CIT0020","first-page":"400","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0021","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn\u2019s disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0022","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181012112705085_CIT0023","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/MIB.0b013e318281f538","article-title":"Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease","volume":"19","author":"Parikh","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0024","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/apt.13960","article-title":"Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease","volume":"45","author":"Mahadevan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20181012112705085_CIT0025","volume-title":"Investigational New Drug Application, 21 C.F.R. \u00a7 312.32","author":"US Food and Drug Administration","year":"2016"},{"key":"key\n\t\t\t\t20181012112705085_CIT0026","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/j.1572-0241.2007.01780.x","article-title":"A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20181012112705085_CIT0027","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2036.2010.04548.x","article-title":"Systematic review: Clostridium difficile and inflammatory bowel disease","volume":"33","author":"Goodhand","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20181012112705085_CIT0028","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrgastro.2012.87","article-title":"IBD: poor outcomes after Clostridium difficile infection in IBD","volume":"9","author":"Khanna","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20181012112705085_CIT0029","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/MIB.0000000000000696","article-title":"Host immune response to Clostridium difficile infection in inflammatory bowel disease patients","volume":"22","author":"Hughes","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40168-017-0269-3","article-title":"Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease","volume":"5","author":"Khanna","year":"2017","journal-title":"Microbiome"},{"key":"key\n\t\t\t\t20181012112705085_CIT0031","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181012112705085_CIT0032","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7071.1","article-title":"Progressive multifocal leukoencephalopathy","volume":"4","author":"Adang","year":"2015","journal-title":"F1000Res"},{"key":"key\n\t\t\t\t20181012112705085_CIT0033","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20181012112705085_CIT0034","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.08.011","article-title":"Vedolizumab, a monoclonal antibody to the gut homing \u03b14\u03b27 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype","volume":"264","author":"Milch","year":"2013","journal-title":"J Neuroimmunol"},{"key":"key\n\t\t\t\t20181012112705085_CIT0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.17235\/reed.2016.4440\/2016","article-title":"Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization","volume":"108","author":"Riestra","year":"2016","journal-title":"Rev Esp Enferm Dig"},{"key":"key\n\t\t\t\t20181012112705085_CIT0036","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20181012112705085_CIT0037","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn\u2019s disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20181012112705085_CIT0038","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t20181012112705085_CIT0039","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ecco-jcc\/jjw129","article-title":"Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort","volume":"10","author":"Abitbol","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0040","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/ecco-jcc\/jjw022","article-title":"Tuberculosis in anti-tumour necrosis factor-treated inflammatory bowel disease patients after the implementation of preventive measures: compliance with recommendations and safety of retreatment","volume":"10","author":"Carpio","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20181012112705085_CIT0041","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"},{"key":"key\n\t\t\t\t20181012112705085_CIT0042","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/2042098613490780","article-title":"Monitoring product safety in the postmarketing environment","volume":"4","author":"Sharrar","year":"2013","journal-title":"Ther Adv Drug Saf"},{"key":"key\n\t\t\t\t20181012112705085_CIT0043","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.4103\/0976-500X.120941","article-title":"Pharmacovigilance in Asia","volume":"4","author":"Biswas","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"key\n\t\t\t\t20181012112705085_CIT0044","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"S\u00f8rensen","year":"2012","journal-title":"Mult Scler"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/11\/2431\/26034734\/izy153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T14:34:26Z","timestamp":1572100466000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/11\/2431\/4993052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,4]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,5,4]]},"published-print":{"date-parts":[[2018,10,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy153","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,5,4]]}}}